Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Active Psoriatic Arthritis (SOLSTICE)
NCT04936308Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in psoriatic arthritis (PsA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: American College of Rheumatology 20 Response at 24 weeks. Started Sep 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04936308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936308.